ARCHIVES

FDA Commissioner Says Swifter Drug Approvals, Enforcement Emphasis Characterize ‘Today’s FDA’

This article is from The Cancer Letter archive.

Vol. 18 No. 05 | January 31, 1992

Download PDF Visit The Full Archive

Related Articles

IOM Committee Will Probe Duke Scandal Together With Other “Omics” Case Studies

January 7, 2011

Minority Demonstration Centers Concept

May 12, 1989

NIH Reauthorization Still Lingering, Bills ‘Tie Hands’ Of NCI Director

October 18, 1991

Research Program For Biological Response Modifiers Outlined By DCT board Subcommittee

November 16, 1979

New Risk Stratification Method For Prostate Cancer Described

November 28, 2003

Guest Editorial: Guideline Promises to End Twenty-Year War Over Mass Screening for Prostate Cancer

May 24, 2013